Tags

Type your tag names separated by a space and hit enter

PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper Vipera berus nikolskii.
Toxins (Basel). 2020 May 29; 12(6)T

Abstract

Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites to be treated only with antihistamines and supportive therapy. Varespladib is an effective inhibitor of snake phospholipase, and, as such, it could be considered as first-line therapy. The Nikolsky's viper venom contains an extremely high concentration of phospholipase A2 (PLA2), responsible for the toxic effects of the venom, as well as minor amounts of other toxins. If Varespladib can successfully inhibit PLA2 activity, the Nikolsky's viper could be one of the first venomous snakes having an antitoxin-specific treatment regimen. To assess that, Varespladib was administered alone subcutaneously to adult male CD-1 mice (8 mg/kg) and compared to mice exposed to Vipera berus nikolskii crude venom (8 mg/kg = 10 LD50) or a combination of Varespladib and the same amount of the venom. Experimental animals were monitored for the presence of envenoming symptoms and mortality for 48 h after injection. Eighty percent of mice receiving both Varespladib and venom survived, while 100% of the control group receiving venom alone died within 4 h. Experimental results are consistent with Varespladib acting as an effective antitoxin in the mouse model against Nikolsky's viper venom. Further studies are needed under experimental conditions that more closely resemble natural envenoming (i.e., delayed administration).

Authors+Show Affiliations

V. N. Karazin Kharkiv University, 61058 Kharkiv, Ukraine.Ukrainian Independent Ecology Institute, 61001 Kharkiv, Ukraine.V. N. Karazin Kharkiv University, 61058 Kharkiv, Ukraine.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32485836

Citation

Zinenko, Oleksandr, et al. "PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites From Nikolsky's Viper Vipera Berus Nikolskii." Toxins, vol. 12, no. 6, 2020.
Zinenko O, Tovstukha I, Korniyenko Y. PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper Vipera berus nikolskii. Toxins (Basel). 2020;12(6).
Zinenko, O., Tovstukha, I., & Korniyenko, Y. (2020). PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper Vipera berus nikolskii. Toxins, 12(6). https://doi.org/10.3390/toxins12060356
Zinenko O, Tovstukha I, Korniyenko Y. PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites From Nikolsky's Viper Vipera Berus Nikolskii. Toxins (Basel). 2020 May 29;12(6) PubMed PMID: 32485836.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper Vipera berus nikolskii. AU - Zinenko,Oleksandr, AU - Tovstukha,Igor, AU - Korniyenko,Yevgen, Y1 - 2020/05/29/ PY - 2019/08/12/received PY - 2019/08/27/revised PY - 2019/08/27/accepted PY - 2020/6/4/entrez KW - PLA2 KW - Varespladib KW - Viperidae KW - inhibitor KW - mouse KW - snakebite KW - therapy JF - Toxins JO - Toxins (Basel) VL - 12 IS - 6 N2 - Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites to be treated only with antihistamines and supportive therapy. Varespladib is an effective inhibitor of snake phospholipase, and, as such, it could be considered as first-line therapy. The Nikolsky's viper venom contains an extremely high concentration of phospholipase A2 (PLA2), responsible for the toxic effects of the venom, as well as minor amounts of other toxins. If Varespladib can successfully inhibit PLA2 activity, the Nikolsky's viper could be one of the first venomous snakes having an antitoxin-specific treatment regimen. To assess that, Varespladib was administered alone subcutaneously to adult male CD-1 mice (8 mg/kg) and compared to mice exposed to Vipera berus nikolskii crude venom (8 mg/kg = 10 LD50) or a combination of Varespladib and the same amount of the venom. Experimental animals were monitored for the presence of envenoming symptoms and mortality for 48 h after injection. Eighty percent of mice receiving both Varespladib and venom survived, while 100% of the control group receiving venom alone died within 4 h. Experimental results are consistent with Varespladib acting as an effective antitoxin in the mouse model against Nikolsky's viper venom. Further studies are needed under experimental conditions that more closely resemble natural envenoming (i.e., delayed administration). SN - 2072-6651 UR - https://www.unboundmedicine.com/medline/citation/32485836/PLA2_Inhibitor_Varespladib_as_an_Alternative_to_the_Antivenom_Treatment_for_Bites_from_Nikolsky's_Viper_Vipera_berus_nikolskii L2 - https://www.mdpi.com/resolver?pii=toxins12060356 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.